Based on this premise, our studies demonstrated the first evidence that a combination of the PARP inhibitors and a small compound named SN-38, which individually have poor therapeutic effects, exhibited a greatly synergistic impact on BRCA1/2-proficient ovarian cancer. This evidence concerns the gene PARP1 and ovarian carcinoma.